Skip to content
A discussion of SLS-002 (intranasal racemic ketamine), Seelos Therapeutics’ registration directed study that is currently enrolling in a randomized, double-blind, placebo-controlled study. The purpose of the study is to evaluate the efficacy, safety, and tolerability of repeat doses of SLS-002 in addition to standard of care on the symptoms of MDD and suicidality in patients who are assessed to be at an imminent risk of suicide.

Details

  • Second Stage
Date:
11/05/2022
Start Time:
1:10 pm
End Time:
13:55

Dr. Tim Whitaker, MD

Chief Medical Officer, Seelos Therapeutics

Tim brings over 26 years of experience in the pharmaceutical industry and previous 8 years in academic medicine. His pharmaceutical industry experience involves extensive leadership and management of …

Raj Mehra, PhD

Chairman and CEO, Seelos Therapeutics

Dr. Raj Mehra has been Chief Executive Officer and Chairman of the Board of Directors at Seelos Therapeutics since January 2019. Prior to founding Seelos, Dr. Mehra spent nine years at Auriga USA, LLC…

Dr. Dean Burnett, PhD

Neuroscience author, DB Publications Ltd.

Dean Burnett is a doctor of neuroscience and experienced psychiatry lecturer and teacher, educating postgraduate students on all matters of the science of mental health, how it works, and how it’s tre…

Get Recordings Now!

Easily access the recordings for your favorite Wonderland sessions, allowing you to revisit the discussions and insights shared by our visionary speakers.

Buy Now